Does ADAGRASIB Cause Hepatic cytolysis? 11 Reports in FDA Database

Q: Does ADAGRASIB cause Hepatic cytolysis?

11 reports of Hepatic cytolysis have been filed with the FDA for ADAGRASIB, representing 1.2% of all ADAGRASIB adverse event reports.

Q: How dangerous is Hepatic cytolysis from ADAGRASIB?

Of 11 reports, 3 (27.3%) resulted in death and 7 required hospitalization.

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 11 reports of Hepatic cytolysis have been filed in association with ADAGRASIB (KRAZATI). This represents 1.2% of all adverse event reports for ADAGRASIB.

Reports of Hepatic cytolysis with ADAGRASIB

1.2%

of all ADAGRASIB reports

Deaths

Hospitalizations

How Dangerous Is Hepatic cytolysis From ADAGRASIB?

Of the 11 reports, 3 (27.3%) resulted in death, 7 (63.6%) required hospitalization, and 3 (27.3%) were considered life-threatening.

Is Hepatic cytolysis Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ADAGRASIB. However, 11 reports have been filed with the FAERS database.

What Other Side Effects Does ADAGRASIB Cause?

Death (272) Diarrhoea (113) Hospitalisation (108) Nausea (87) Vomiting (79) Off label use (70) Asthenia (61) Fatigue (51) Decreased appetite (43) Dehydration (35)

What Other Drugs Cause Hepatic cytolysis?

ACETAMINOPHEN (1,469) ATORVASTATIN (681) PEMBROLIZUMAB (601) CARBOPLATIN (577) METHOTREXATE (468) SULFAMETHOXAZOLE\TRIMETHOPRIM (356) PACLITAXEL (324) ENOXAPARIN (307) AMOXICILLIN (273) VALACYCLOVIR (261)

Which ADAGRASIB Alternatives Have Lower Hepatic cytolysis Risk?

ADAGRASIB vs ADALIMUMAB ADAGRASIB vs ADALIMUMAB-AACF ADAGRASIB vs ADALIMUMAB-AATY ADAGRASIB vs ADALIMUMAB-ADAZ ADAGRASIB vs ADALIMUMAB-ADBM

ADAGRASIB Full Profile All Hepatic cytolysis Reports All Drugs Causing Hepatic cytolysis ADAGRASIB Demographics